Clinical Trial for Xerostomia

Do you suffer from moderate or severe dry mouth after radiation therapy?

MeiraGTx is currently enrolling patients with moderate or severe xerostomia resulting from radiation therapy for head and neck cancer. The trial is called the AQUAx2 study.

Learn more

MeiraGTx has partnered with Side Effect Support to help spread the word on this important ongoing study that will determine if the investigational gene therapy, AAV2-hAQP1 (the study drug), has an effect on dry mouth symptoms and the amount of saliva produced, and to see if it is safe and well-tolerated. 

The procedure for administering the study drug takes place in a physician’s or dentist’s office. The participant opens their mouth, and the investigator inserts a very small catheter into each parotid salivary gland and then infuses the study drug into the glands. The procedure, which takes about 15 minutes per side, requires no anesthesia. Study participation will last for about one year. At the end of the AQUAx2 study, participants will be invited to enroll in a separate long-term follow-up study. All trial-related services are provided at no cost.

The trial is “A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia (AQUAX2).”

If you are interested in participating, we encourage you to visit the AQUAx2 study website to determine if you qualify. Alternatively, you can reach out to the MeiraGTx team by email at patients@meiragtx.com.

Please reference the “AQUAx2 study” when contacting MeiraGTx. Participation in research is always voluntary, and you will be asked to review and sign an informed consent form before any trial-related assessments are performed. You always retain the right to withdraw from the trial for any reason.

Thank you for your interest!

Learn more